These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 31734763)

  • 1. The plasminogen activator inhibitor-1 paradox in cancer: a mechanistic understanding.
    Kubala MH; DeClerck YA
    Cancer Metastasis Rev; 2019 Sep; 38(3):483-492. PubMed ID: 31734763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasminogen activator inhibitor-1 in cancer research.
    Li S; Wei X; He J; Tian X; Yuan S; Sun L
    Biomed Pharmacother; 2018 Sep; 105():83-94. PubMed ID: 29852393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasminogen Activator Inhibitor-1 Promotes the Recruitment and Polarization of Macrophages in Cancer.
    Kubala MH; Punj V; Placencio-Hickok VR; Fang H; Fernandez GE; Sposto R; DeClerck YA
    Cell Rep; 2018 Nov; 25(8):2177-2191.e7. PubMed ID: 30463014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer.
    Duffy MJ; Duggan C
    Clin Biochem; 2004 Jul; 37(7):541-8. PubMed ID: 15234235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular competition between plasminogen activator inhibitors type -1 and -2 for urokinase: Implications for cellular proteolysis and adhesion in cancer.
    Lobov S; Ranson M
    Cancer Lett; 2011 Apr; 303(2):118-27. PubMed ID: 21316840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis.
    Skeldal S; Larsen JV; Pedersen KE; Petersen HH; Egelund R; Christensen A; Jensen JK; Gliemann J; Andreasen PA
    FEBS J; 2006 Nov; 273(22):5143-59. PubMed ID: 17042782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The plasminogen activator inhibitor "paradox" in cancer.
    Binder BR; Mihaly J
    Immunol Lett; 2008 Jun; 118(2):116-24. PubMed ID: 18495253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical relevance of the plasminogen activator inhibitor type 1--a multifaceted proteolytic factor.
    Harbeck N; Krüger A; Sinz S; Kates RE; Thomssen C; Schmitt M; Jänicke F
    Onkologie; 2001 Jun; 24(3):238-44. PubMed ID: 11455216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Binding of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex to the endocytosis receptors alpha2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor.
    Rodenburg KW; Kjoller L; Petersen HH; Andreasen PA
    Biochem J; 1998 Jan; 329 ( Pt 1)(Pt 1):55-63. PubMed ID: 9405275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies.
    Duffy MJ; McGowan PM; Harbeck N; Thomssen C; Schmitt M
    Breast Cancer Res; 2014 Aug; 16(4):428. PubMed ID: 25677449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The complex between urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-I) independently predicts response to first-line endocrine therapy in advanced breast cancer.
    Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot AJ; van Tienoven DT; Beex LV; Sweep FC
    Thromb Haemost; 2004 Mar; 91(3):514-21. PubMed ID: 14983227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The urokinase-type plasminogen activator system and its role in tumor progression].
    Kugaevskaya EV; Gureeva TA; Timoshenko OS; Solovyeva NI
    Biomed Khim; 2018 Nov; 64(6):472-486. PubMed ID: 30632975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphatidylinositol 3-kinase/Akt regulates the balance between plasminogen activator inhibitor-1 and urokinase to promote migration of SKOV-3 ovarian cancer cells.
    Whitley BR; Beaulieu LM; Carter JC; Church FC
    Gynecol Oncol; 2007 Feb; 104(2):470-9. PubMed ID: 17070899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interfering with the inhibitory mechanism of serpins: crystal structure of a complex formed between cleaved plasminogen activator inhibitor type 1 and a reactive-centre loop peptide.
    Xue Y; Björquist P; Inghardt T; Linschoten M; Musil D; Sjölin L; Deinum J
    Structure; 1998 May; 6(5):627-36. PubMed ID: 9634700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor stroma is the predominant uPA-, uPAR-, PAI-1-expressing tissue in human breast cancer: prognostic impact.
    Hildenbrand R; Schaaf A; Dorn-Beineke A; Allgayer H; Sütterlin M; Marx A; Stroebel P
    Histol Histopathol; 2009 Jul; 24(7):869-77. PubMed ID: 19475533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling.
    Stefansson S; McMahon GA; Petitclerc E; Lawrence DA
    Curr Pharm Des; 2003; 9(19):1545-64. PubMed ID: 12871067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of mouse models to study plasminogen activator inhibitor-1.
    Declerck PJ; Gils A; De Taeye B
    Methods Enzymol; 2011; 499():77-104. PubMed ID: 21683250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The urokinase plasminogen activation system in gastroesophageal cancer: A systematic review and meta-analysis.
    Brungs D; Chen J; Aghmesheh M; Vine KL; Becker TM; Carolan MG; Ranson M
    Oncotarget; 2017 Apr; 8(14):23099-23109. PubMed ID: 28416743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression, Intracellular Localization, and Prognostic Value of Plasminogen Activator Inhibitor 1 and PAI-1 RNA-Binding Protein 1 in Primary and Recurrent Ovarian Cancer: A Study of the Tumor Bank Ovarian Cancer Network.
    Koensgen D; Stope MB; Tuerbachova I; Bruennert D; Kohlmann T; Braicu I; Sehouli J; Denkert C; Darb-Esfahani S; Stickeler E; Sofroni D; Dahl E; Mustea A
    Gynecol Obstet Invest; 2018; 83(5):508-514. PubMed ID: 28738361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The apparent uPA/PAI-1 paradox in cancer: more than meets the eye.
    Kwaan HC; Mazar AP; McMahon BJ
    Semin Thromb Hemost; 2013 Jun; 39(4):382-91. PubMed ID: 23532574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.